Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
This activity will review the latest PK recommendations for Factor VIII and IX replacement and how to use and interpret PK parameters to assess treatment plans.
Choose from the criteria below to find an activity that fits you best.
Note: If you attended the live CE activity AND received CE credit (i.e. a pharmacist CE statement of credit with ACPE UAN 0221-9999-19-199-L01-P), you are NOT allowed to also receive credit for this home-study on-demand web activity.
|A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC)|
Rabies is a prolifically deadly zoonotic disease. In the United States, the rabies virus (RABV) is most often transmitted by infected wild animal vectors, such as bats, foxes, skunks, and raccoons. Rabies-related human deaths are infrequent due to prophylaxis using vaccines and human rabies immunoglobulin (HRIG), providing nearly 100% success rates. Fatalities from rabies occurs when patients fail to seek medical attention. While this does not occur often, preventable deaths were reported within the last year. Because of the relative infrequency that clinical, emergency department, and pharmacy directors may have with rabies, it is critical to understand the infection and necessary steps to procure and administer human rabies immunoglobulin and the rabies vaccine. Importantly, pharmacists and other members of the healthcare team should be adequately educated on practical preparation and timing of treatment, monitoring, and safety considerations.
The target audience for this activity includes pharmacists. At the completion of this activity, the participant will be able to:
Nicole M. Acquisto, Pharm.D., FCCP, BCCCP
Emergency Medicine Clinical Pharmacy Specialist, Department of Pharmacy
Associate Professor, Department of Emergency Medicine
University of Rochester Medical Center
Rochester, New York
Release Date: August 15, 2019
Expiration Date: August 15, 2020
This activity is jointly provided by ProCE, Inc. and the Society of Infectious Diseases Pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-19-199-H01-P has been assigned to this home study knowledge-based activity. This activity is approved for 1.0 contact hours (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Acquisto has no relevant commercial or financial relationships to disclose.
This activity is supported by an educational grant from Kedrion Biopharma, Inc.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.